Vaccine hesitancy in people with multiple sclerosis

Lechner‐Scott, Jeannette; Davis, Joshua S.; Hawkes, Christopher H.; Giovannoni, Gavin; Levy, Michaël; Yeh, Ann Ming

doi:10.1016/j.msard.2022.104102

Cited by 5 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although more than 5 billion people have been vaccinated worldwide(https://covid19.who.int. ),results from some investigative studies demonstrate that there are still 10%-20% of patients with neuroimmune diseases are hesitant to vaccinate [44] , and there are many reasons for hesitation, but the most common reasons were concerns about vaccine safety [45] .A better clarification of the safety of COVID-19 vaccination in ANC patients is therefore crucial to help reduce their vaccine hesitancy and bring the COVID-19 pandemic under control.…”

Section: Discussionmentioning

confidence: 99%

Safety of SARS-CoV-2 vaccine in patients with autoimmune neurological conditions: a systematic review and meta-analysis

Ning

Cao

Wang

et al. 2023

Preprint

View full text Add to dashboard Cite

Risk of adverse effects and exacerbation in autoimmune neurological conditions(ANC)are frequently cited reasons for COVID-19 vaccine hesitancy. This study evaluates the ANC safety of COVID-19 vaccines in the real world. We selected studies that provided data on the occurrence of adverse effects and exacerbation of conditions related to ANC after vaccination. The pooled incidence rates for various adverse effects, stratified for the disease category, dosage, and type of vaccine were estimated. Twenty-eight studies (31 vaccination cohorts) were included. The pooled incidence rate of general adverse events was 0.35 (95%CI, 0.27–0.43, I = 100%). The pooled incidence rate of exacerbation adverse events was 0.05(95%CI, 0.04-0.07, I = 84%). The pooled incidence rates of local injection reaction, fatigue, weakness, myalgia, fever, headache, and chills were 0.27 (0.18–0.36, I = 98%), 0.16(0.11-0.21, I = 93%), 0.15(0.00-0.31, I = 97%), 0.13(0.08-0.19, I = 97%), 0.11(0.07-0.15, I = 95%), 0.11(0.07-0.16, I = 97%), and0.09(0.03-0.16, I = 96%), respectively. According to available evidence, the administration of COVID-19 vaccines in individuals with ANC seems to be well-tolerated, with few reports of adverse events. Furthermore, exacerbation of ANC following vaccination appears to be infrequent.

show abstract

Section: Discussionmentioning

confidence: 99%

Safety of SARS-CoV-2 vaccine in patients with autoimmune neurological conditions: a systematic review and meta-analysis

Ning

Cao

Wang

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…In addition, the immunosuppressive or immunomodulatory activity of disease-modifying treatments (DMTs) affect the immune response to the vaccine [5,6]. Given this, there is a degree of hesitancy among MS patients to be vaccinated against COVID-19 [7][8][9].…”

mentioning

confidence: 99%

COVID‐19 vaccination and relapse activity: A nationwide cohort study of patients with multiple sclerosis in Denmark

Stastna,

Elberling,

Pontieri

et al. 2023

Euro J of Neurology

View full text Add to dashboard Cite

Background and purposeWe evaluated whether there was a difference in the occurrence of relapses pre‐ and post‐COVID‐19 vaccination in a nationwide cohort of Danish patients with relapsing multiple sclerosis.MethodsWe conducted a population‐based, nationwide cohort study with a cutoff date of 1 October 2022. We used McNemar tests to assess changes in the proportion of patients with recorded relapses within 90 days and 180 days before and after first vaccine dose, and a negative binomial regression model to compare the 90 and 180 days postvaccination annualized relapse rate (ARR) to the 360 days prevaccination ARR. Multivariate Cox regression was used to estimate relapse risk factors.ResultsWe identified 8169 vaccinated (87.3% Comirnaty) patients without a recorded history of a positive COVID‐19 test. We did not find statistically significant changes in the proportion of patients with relapses in the 90 days (1.3% vs. 1.4% of patients, p = 0.627) and 180 days (2.7% vs. 2.6% of patients, p = 0.918) pre‐ and postvaccination. Also, a comparison of the ARR 360 days before (0.064, 95% confidence interval [CI] = 0.058–0.070) with the ARR 90 (0.057, 95% CI = 0.047–0.069, p = 0.285) and 180 (0.055, 95% CI = 0.048–0.063, p = 0.060) days after vaccination did not show statistically significant differences. Lower age, higher Expanded Disability Status Scale score, and relapse within 360 days before vaccination were associated with a higher risk of relapse.ConclusionsWe did not find evidence of increased relapse activity following the administration of the first dose of the COVID‐19 vaccine.

show abstract

Impact of COVID-19 disease and COVID-19 vaccinations on hospital admissions for neurological diseases in the Lombardia over-12 population. Data from a self-controlled case series analysis

Salmaggi,

Bortolan,

Ercolanoni

et al. 2024

Neurol Sci

View full text Add to dashboard Cite

Vaccine hesitancy in people with multiple sclerosis

Cited by 5 publications

References 16 publications

Safety of SARS-CoV-2 vaccine in patients with autoimmune neurological conditions: a systematic review and meta-analysis

Safety of SARS-CoV-2 vaccine in patients with autoimmune neurological conditions: a systematic review and meta-analysis

COVID‐19 vaccination and relapse activity: A nationwide cohort study of patients with multiple sclerosis in Denmark

Impact of COVID-19 disease and COVID-19 vaccinations on hospital admissions for neurological diseases in the Lombardia over-12 population. Data from a self-controlled case series analysis

Contact Info

Product

Resources

About